This real-world observational study by La Barbera, et al. confirms that filgotinib is efficacious and safe for use in the management of RA. The authors also report that improvements in clinical and laboratory features were greater in bDMARD-naïve patients with RA.

The study cohort was split into two groups: bDMARD-naïve and bDMARD-IR. These groups were further divided into filgotinib monotherapy and filgotinib + MTX. Patients were assessed at baseline and at Weeks 12 and 24.

Keywords:


Publication thumbnail: Effectiveness and Safety of Filgotinib in Rheumatoid Arthritis: A Real-life Multicentre Experience
LinkedIn